Journal of Neuroimmunology
Volume 229, Issue 1 , Pages 225-231 , 15 December 2010

Common variation in the MOG gene influences transcript splicing in humans

  • Cathy J. Jensen

      Affiliations

    • The Florey Neuroscience Institutes, University of Melbourne, Victoria, Australia
    • Department of Physiology, Monash University, Clayton, Victoria, Australia
    • ,
  • Jim Stankovich

      Affiliations

    • Menzies Research Institute, University of Tasmania, Hobart, Australia
    • ,
  • Helmut Butzkueven

      Affiliations

    • The Florey Neuroscience Institutes, University of Melbourne, Victoria, Australia
    • Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Australia
    • ,
  • Brian J. Oldfield

      Affiliations

    • Department of Physiology, Monash University, Clayton, Victoria, Australia
    • ,
  • Justin P. Rubio

      Affiliations

    • The Florey Neuroscience Institutes, University of Melbourne, Victoria, Australia
    • Corresponding Author InformationCorresponding author. Genetics Division, Research and Development, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom. Tel.: +44 1279 627 973; fax: +44 1279 875 363.

Received 5 May 2010 ,Revised 16 July 2010 ,Accepted 27 July 2010.

References 

  1. Allamargot C, Gardinier MV. Alternative isoforms of myelin/oligodendrocyte glycoprotein with variable cytoplasmic domains are expressed in human brain. Journal of Neurochemistry. 2007;101:298–312
  2. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263–265
  3. Bergamaschi L, Leone MA, Fasano ME, Guerini FR, Ferrante D, Bolognesi E, et al. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes and Immunity. 2009;11:173–180
  4. Boyle LH, Traherne JA, Plotnek G, Ward R, Trowsdale J. Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport1. Journal of Neurochemistry. 2007;102:1853–1862
  5. Bray NJ, O'Donovan MC. Investigating cis-acting regulatory variation using assays of relative allelic expression. Psychiatric Genetics. 2006;16:173–177
  6. Burfoot RK, Jensen CJ, Field J, Stankovich J, Varney MD, Johnson LJ, et al. SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. Tissue Antigens. 2008;71:42–50
  7. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Research. 2003;31:3568–3571
  8. Collin RW, de Heer AM, Oostrik J, Pauw RJ, Plantinga RF, Huygen PL, et al. Mid-frequency DFNA8/12 hearing loss caused by a synonymous TECTA mutation that affects an exonic splice enhancer. European Journal of Human Genetics. 2008;16:1430–1436
  9. D'Alfonso S, Bolognesi E, Guerini FR, Barizzone N, Bocca S, Ferrante D, et al. A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy. Genes and Immunity. 2008;9(1):7–15
  10. Delarasse C, Della Gaspera B, Lu CW, Lachapelle F, Gelot A, Rodriguez D, et al. Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates. Journal of Neurochemistry. 2006;98:1707–1717
  11. Dyer CA, Matthieu J-M. Antibodies to myelin/oligodendrocyte-specific protein and myelin/oligodendrocyte glycoprotein signal distinct changes in the organization of cultured oligodendroglial membrane sheets. Journal of Neurochemistry. 1994;62:777–787
  12. Gibbs R, Belmont J, Hardenbol P, Willis T, Yu F, Yang H. The international HapMap project. Nature. 2003;426:789
  13. Gomez-Lira M, Moretto G, Bonamini D, Benedetti MD, Pignatti PF, Rizzuto N, et al. Myelin oligodendrocyte glycoprotein polymorphisms and multiple sclerosis. Journal of Neuroimmunology. 2002;133:241
  14. Graveley BR. Sorting out the complexity of SR protein functions. RNA. 2000;6:1197–1211
  15. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nature Genetics. 2007;39:1083
  16. Johns TG, Bernard CCA. The structure and function of myelin oligodendrocyte glycoprotein. J. Neurochem. 1999;72:1–9
  17. Kerlero de Rosbo N, Hoffman M, Mendel I, Yust I, Kaye J, Bakimer R, et al. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. European Journal of Immunology. 1997;27:3059–3069
  18. Lebar R, Lubetzki C, Vincent C, Lombrail P, Boutry J. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clinical & Experimental Immunology. 1986;66:423–434
  19. Long JC, Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochemistry Journal. 2009;417:15–27
  20. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nature Genetics. 2007;39:1108–1113
  21. Marta CB, Taylor CM, Coetzee T, Kim T, Winkler S, Bansal R, et al. Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology. Journal of Neuroscience. 2003;23:5461–5471
  22. Marta CB, Montano MB, Taylor CM, Taylor AL, Bansal R, Pfeiffer SE. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis. Journal of Biological Chemistry. 2005;280:8985–8993
  23. Marta CB, Oliver AR, Sweet RA, Pfeiffer SE, Ruddle NH. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proceedings of the National Academy of Sciences. 2005;102:13992–13997
  24. Menon KN, Gardinier MV. The cytoplasmic domain of MOG interacts with stathmin, a regulator of microtubule dynamics. Mol. Biol. Cell. 2004;15:170A-170A
  25. Ohtani S, Kohyama K, Matsumoto Y. Autoantibodies recognizing native MOG are closely associated with active demyelination but not with neuroinflammation in chronic EAE. Neuropathology. 2010;doi:10.1111/j.1440-1789.2010.01131.x
  26. Oliveira J, Soares-Silva I, Fokkema I, Goncalves A, Cabral A, Diogo L, et al. Novel synonymous substitution in POMGNT1 promotes exon skipping in a patient with congenital muscular dystrophy. Journal of Human Genetics. 2008;53:565–572
  27. Pham-Dinh D, Dg B, Kdr N, D.A. . Structure of the human myelin/oligodendrocyte glycoprotein gene and multiple alternative spliced isoforms. Genomics. 1995;29:345
  28. Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, Bernard CCA. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 1998;28:109–120
  29. Tomassini V, De Giglio L, Reindl M, Russo P, Pestalozza I, Pantano P, et al. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS. Multiple Sclerosis. 2007;13:1086–1094
  30. Wang H, Munger KL, Reindl M, O'Reilly EJ, Levin LI, Berger T, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology. 2008;71:1142–1146
  31. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Bruck W, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proceedings of the National Academy of Sciences. 2006;103:19057–19062

PII: S0165-5728(10)00340-1

doi: 10.1016/j.jneuroim.2010.07.027

Journal of Neuroimmunology
Volume 229, Issue 1 , Pages 225-231 , 15 December 2010

Article Tools

* Image Usage & Resolution